Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...

Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...

Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...

In an awake individual, mild-to-moderate nocturnal hypoglycemia is easily corrected by ingesting a snack containing approximately 5 g of fast-acting carbohydrate ... the basal insulin, a bedtime ...

Admelog has also been approved in Europe as a biosimilar under the name Insulin ... its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba ...

Some diabetes patients in the U.S. have this year pushed back against the company's decision to stop selling its long-acting insulin Levemir, which is an analogue insulin. They say the move has ...

To mimic physiological insulin release, both long-acting and short-acting insulin preparations are needed. After decades of optimizations to develop longer-acting insulin preparations to reduce ...

People with Type 1 or 1.5 diabetes rely on both short acting and long acting insulin. Short acting insulin manages their blood sugar after eating and long acting insulin prevents the liver from ...

Crucially, the long-acting insulin was no worse than Tresiba when it came to rates of hypoglycaemia, when blood glucose levels dip too low, according to statistical comparisons between the drugs.